The Huntington Study Group (HSG) shared that the Phase 3 KINECT-HD study resulted in FDA approval of valbenazine for treatment of chorea in Huntington’s disease (HD). As a vesicular monoamine transporter 2 (VMAT2) inhibitor, valbenazine reduced chorea symptoms as early as two weeks after initial dose.
Read the full press release here: https://huntingtonstudygroup.org/news/huntington-study-group-welcomes-fda-approval-of-new-drug-for-chorea-in-huntingtons-disease/